Published in Cell on June 20, 2013
CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia Maintenance. Cancer Cell (2015) 2.20
Genome-wide mapping and characterization of Notch-regulated long noncoding RNAs in acute leukemia. Cell (2014) 1.88
Clonal evolution enhances leukemia-propagating cell frequency in T cell acute lymphoblastic leukemia through Akt/mTORC1 pathway activation. Cancer Cell (2014) 1.79
From fly wings to targeted cancer therapies: a centennial for notch signaling. Cancer Cell (2014) 1.70
Cyclin C is a haploinsufficient tumour suppressor. Nat Cell Biol (2014) 1.68
An overview of MYC and its interactome. Cold Spring Harb Perspect Med (2014) 1.53
Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities. Cancer Cell (2014) 1.51
Roles of F-box proteins in cancer. Nat Rev Cancer (2014) 1.51
Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature (2014) 1.47
SCF ubiquitin ligase-targeted therapies. Nat Rev Drug Discov (2014) 1.25
Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc Natl Acad Sci U S A (2014) 1.25
c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood (2014) 1.23
Edgotype: a fundamental link between genotype and phenotype. Curr Opin Genet Dev (2013) 1.12
Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence. Ther Adv Hematol (2015) 1.06
The zinc finger transcription factor ZFX is required for maintaining the tumorigenic potential of glioblastoma stem cells. Stem Cells (2014) 1.05
Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet (2016) 1.05
Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. J Clin Invest (2015) 1.03
BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through Bim induction. Cell Rep (2013) 1.01
The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer (2016) 1.00
CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress. Oncogene (2014) 0.99
Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma. Leukemia (2014) 0.98
Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia, T-ALL. Oncotarget (2014) 0.97
Role of Fbxw7 in the maintenance of normal stem cells and cancer-initiating cells. Br J Cancer (2014) 0.93
p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma. Mol Cancer Res (2014) 0.91
ZFX controls propagation and prevents differentiation of acute T-lymphoblastic and myeloid leukemia. Cell Rep (2014) 0.89
New Approaches to Target T-ALL. Front Oncol (2014) 0.88
A microRNA-mediated regulatory loop modulates NOTCH and MYC oncogenic signals in B- and T-cell malignancies. Leukemia (2014) 0.87
Enhancers of Polycomb EPC1 and EPC2 sustain the oncogenic potential of MLL leukemia stem cells. Leukemia (2013) 0.87
Leukemia stem cells in T-ALL require active Hif1α and Wnt signaling. Blood (2015) 0.86
Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients. BMC Cancer (2015) 0.84
The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors. Cell Death Dis (2014) 0.84
SCL, LMO1 and Notch1 reprogram thymocytes into self-renewing cells. PLoS Genet (2014) 0.84
PI3K inhibition synergizes with glucocorticoids but antagonizes with methotrexate in T-cell acute lymphoblastic leukemia. Oncotarget (2015) 0.84
Haploinsufficiency of the c-myc transcriptional repressor FIR, as a dominant negative-alternative splicing model, promoted p53-dependent T-cell acute lymphoblastic leukemia progression by activating Notch1. Oncotarget (2015) 0.83
MYC is a critical target of FBXW7. Oncotarget (2015) 0.83
Activated Notch counteracts Ikaros tumor suppression in mouse and human T-cell acute lymphoblastic leukemia. Leukemia (2015) 0.83
Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma. Oncotarget (2015) 0.82
Targeting leukemia stem cells: which pathways drive self-renewal activity in T-cell acute lymphoblastic leukemia? Curr Oncol (2016) 0.81
FBXW7 modulates cellular stress response and metastatic potential through HSF1 post-translational modification. Nat Cell Biol (2015) 0.81
Emerging roles for the FBXW7 ubiquitin ligase in leukemia and beyond. Curr Opin Cell Biol (2015) 0.81
Targeting the MYC and PI3K pathways eliminates leukemia-initiating cells in T-cell acute lymphoblastic leukemia. Cancer Res (2014) 0.81
FBXW7 acts as an independent prognostic marker and inhibits tumor growth in human osteosarcoma. Int J Mol Sci (2015) 0.81
Supraphysiologic levels of the AML1-ETO isoform AE9a are essential for transformation. Proc Natl Acad Sci U S A (2016) 0.80
Protein ubiquitination in lymphoid malignancies. Immunol Rev (2015) 0.80
Identification of a Novel Proto-oncogenic Network in Head and Neck Squamous Cell Carcinoma. J Natl Cancer Inst (2015) 0.80
F-box protein FBXO22 mediates polyubiquitination and degradation of KLF4 to promote hepatocellular carcinoma progression. Oncotarget (2015) 0.79
F-box and WD repeat domain-containing-7 (Fbxw7) protein targets endoplasmic reticulum-anchored osteogenic and chondrogenic transcriptional factors for degradation. J Biol Chem (2013) 0.79
microRNA-25 Inhibits Cell Apoptosis of Human Gastric Adenocarcinoma Cell Line AGS via Regulating CCNE1 and MYC. Med Sci Monit (2016) 0.78
Deregulation of F-box proteins and its consequence on cancer development, progression and metastasis. Semin Cancer Biol (2015) 0.78
Mouse models of colorectal cancer as preclinical models. Bioessays (2015) 0.78
ERG promotes the maintenance of hematopoietic stem cells by restricting their differentiation. Genes Dev (2015) 0.78
The ubiquitin ligase Huwe1 regulates the maintenance and lymphoid commitment of hematopoietic stem cells. Nat Immunol (2016) 0.78
Regulation of stem cell function by protein ubiquitylation. EMBO Rep (2014) 0.78
Dependence of Human Colorectal Cells Lacking the FBW7 Tumor Suppressor on the Spindle Assembly Checkpoint. Genetics (2015) 0.77
SMURF1 silencing diminishes a CD44-high cancer stem cell-like population in head and neck squamous cell carcinoma. Mol Cancer (2014) 0.77
Antiinflammatory effects of bromodomain and extraterminal domain inhibition in cystic fibrosis lung inflammation. JCI Insight (2016) 0.77
Inactivation of KLF4 promotes T cell acute lymphoblastic leukemia and activates the MAP2K7 pathway. Leukemia (2016) 0.76
Notching up MYC gives a LIC. Cell Stem Cell (2013) 0.76
β-Catenin is required for T-cell leukemia initiation and MYC transcription downstream of Notch1. Leukemia (2016) 0.76
Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination. J Exp Med (2016) 0.76
The RNA-Binding Proteins Zfp36l1 and Zfp36l2 Enforce the Thymic β-Selection Checkpoint by Limiting DNA Damage Response Signaling and Cell Cycle Progression. J Immunol (2016) 0.76
Oncogenic mutations in the FBXW7 gene of adult T-cell leukemia patients. Proc Natl Acad Sci U S A (2016) 0.76
ELL targets c-Myc for proteasomal degradation and suppresses tumour growth. Nat Commun (2016) 0.76
MYC Deregulation in Primary Human Cancers. Genes (Basel) (2017) 0.75
Oncogenic Notch signaling in T-cell and B-cell lymphoproliferative disorders. Curr Opin Hematol (2016) 0.75
Bromodomain and Extra-Terminal Protein Inhibition Attenuates Neutrophil-dominant Allergic Airway Disease. Sci Rep (2017) 0.75
Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia. Leukemia (2017) 0.75
High selective pressure for Notch1 mutations that induce Myc in T-cell acute lymphoblastic leukemia. Blood (2016) 0.75
FBW7 regulates DNA interstrand cross-link repair by modulating FAAP20 degradation. Oncotarget (2016) 0.75
Collaborating Pathways that Functionally Amplify NOTCH1 Signals in T-Cell Acute Lymphoblastic Leukemia. J Hematol Transfus (2013) 0.75
Guttiferone K impedes cell cycle re-entry of quiescent prostate cancer cells via stabilization of FBXW7 and subsequent c-MYC degradation. Cell Death Dis (2016) 0.75
Therapeutics: Embracing instability. Nat Rev Cancer (2013) 0.75
The homeoprotein Dlx5 drives murine T-cell lymphomagenesis by directly transactivating Notch and upregulating Akt signaling. Oncotarget (2017) 0.75
The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia. Haematologica (2016) 0.75
Bromodomains in Protozoan Parasites: Evolution, Function, and Opportunities for Drug Development. Microbiol Mol Biol Rev (2017) 0.75
The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling. Haematologica (2017) 0.75
Aberrant Signaling Pathways in T-Cell Acute Lymphoblastic Leukemia. Int J Mol Sci (2017) 0.75
Novel tumor suppressor function of KLF4 in pediatric T-cell acute lymphoblastic leukemia. Exp Hematol (2017) 0.75
Inducible gene targeting in mice. Science (1995) 21.22
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 18.84
Selective inhibition of BET bromodomains. Nature (2010) 18.79
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Efficient tumour formation by single human melanoma cells. Nature (2008) 16.35
An extended transcriptional network for pluripotency of embryonic stem cells. Cell (2008) 14.64
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
A landscape of driver mutations in melanoma. Cell (2012) 12.61
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A (2004) 9.42
Transcriptional amplification in tumor cells with elevated c-Myc. Cell (2012) 8.24
Myc's broad reach. Genes Dev (2008) 7.56
Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication. Nature (2001) 7.31
NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A (2006) 6.80
c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell (2012) 6.49
Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A (2011) 6.30
c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev (2006) 6.19
Modelling Myc inhibition as a cancer therapy. Nature (2008) 5.81
Inactivation of hCDC4 can cause chromosomal instability. Nature (2004) 5.71
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature (2011) 5.32
FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med (2007) 4.59
Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell (2010) 4.11
Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. Immunity (2001) 4.09
The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med (2007) 4.04
Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med (2008) 3.98
Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer (2006) 3.89
FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res (2007) 3.79
SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature (2011) 3.69
Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol (2008) 3.57
The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. Mol Cell Biol (2011) 3.01
Oncogenic forms of NOTCH1 lacking either the primary binding site for RBP-Jkappa or nuclear localization sequences retain the ability to associate with RBP-Jkappa and activate transcription. J Biol Chem (1997) 2.93
Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med (2012) 2.86
Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc. Mol Cell Biol (2006) 2.85
Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J Clin Invest (2008) 2.73
Mouse Fbw7/Sel-10/Cdc4 is required for notch degradation during vascular development. J Biol Chem (2003) 2.59
The Pediatric Cancer Genome Project. Nat Genet (2012) 2.49
Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7. J Exp Med (2008) 2.19
Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev (2008) 2.12
Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. J Exp Med (2007) 1.99
A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nat Genet (2011) 1.99
CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature (2009) 1.94
BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proc Natl Acad Sci U S A (2012) 1.93
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med (2012) 1.90
More than just proliferation: Myc function in stem cells. Trends Cell Biol (2005) 1.82
NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity. Blood (2008) 1.69
ChIP-on-chip significance analysis reveals large-scale binding and regulation by human transcription factor oncogenes. Proc Natl Acad Sci U S A (2008) 1.65
Fbw7/hCDC4 dimerization regulates its substrate interactions. Cell Div (2007) 1.64
Gene expression profiling in T-cell acute lymphoblastic leukemia. Semin Hematol (2003) 1.54
Dynamic regulation of c-Myc proto-oncogene expression during lymphocyte development revealed by a GFP-c-Myc knock-in mouse. Eur J Immunol (2008) 1.48
Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. Proc Natl Acad Sci U S A (2009) 1.45
The ubiquitous nature of cancer: the role of the SCF(Fbw7) complex in development and transformation. Oncogene (2010) 1.41
Ubiquitylation of the amino terminus of Myc by SCF(β-TrCP) antagonizes SCF(Fbw7)-mediated turnover. Nat Cell Biol (2010) 1.39
Regulation of hematopoietic stem cell differentiation by a single ubiquitin ligase-substrate complex. Nat Immunol (2010) 1.28
Gene expression profiles during human CD4+ T cell differentiation. Int Immunol (2004) 1.27
Fbw7 and p53 cooperatively suppress advanced and chromosomally unstable intestinal cancer. Mol Cell Biol (2012) 1.17
Multipotent hematopoietic cells susceptible to alternative double-strand break repair pathways that promote genome rearrangements. Genes Dev (2007) 1.10
Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression. Cancer Cell (2013) 1.08
SCF(Fbw7) modulates the NFkB signaling pathway by targeting NFkB2 for ubiquitination and destruction. Cell Rep (2012) 1.03
Tumorigenic cells are common in mouse MPNSTs but their frequency depends upon tumor genotype and assay conditions. Cancer Cell (2012) 0.97
FBXW7 mutations typically found in human cancers are distinct from null alleles and disrupt lung development. J Pathol (2011) 0.89
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature (2004) 8.67
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell (2011) 7.37
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A (2011) 6.30
A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature (2011) 5.78
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med (2007) 4.04
Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A (2009) 4.00
Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med (2008) 3.98
Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell (2003) 3.86
A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell (2005) 3.35
The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest (2012) 3.09
An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol (2006) 2.91
Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med (2012) 2.86
Regulation of immunoglobulin light-chain recombination by the transcription factor IRF-4 and the attenuation of interleukin-7 signaling. Immunity (2008) 2.72
Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat Med (2013) 2.67
PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet (2010) 2.66
Genome-wide and caste-specific DNA methylomes of the ants Camponotus floridanus and Harpegnathos saltator. Curr Biol (2012) 2.50
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell (2012) 2.42
Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J Exp Med (2011) 2.40
Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat Cell Biol (2010) 2.40
An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev (2011) 2.38
Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med (2006) 2.35
Regulation of pluripotency and cellular reprogramming by the ubiquitin-proteasome system. Cell Stem Cell (2012) 2.35
Efficient derivation of purified lung and thyroid progenitors from embryonic stem cells. Cell Stem Cell (2012) 2.33
Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med (2012) 2.24
Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7. J Exp Med (2008) 2.19
The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia. Cancer Cell (2010) 2.09
PRC2 binds active promoters and contacts nascent RNAs in embryonic stem cells. Nat Struct Mol Biol (2013) 2.01
Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res (2008) 1.99
Efficient thymic immigration of B220+ lymphoid-restricted bone marrow cells with T precursor potential. Nat Immunol (2003) 1.97
Self-renewing endodermal progenitor lines generated from human pluripotent stem cells. Cell Stem Cell (2012) 1.94
CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature (2009) 1.94
ETV6 mutations in early immature human T cell leukemias. J Exp Med (2011) 1.88
TET family proteins and their role in stem cell differentiation and transformation. Cell Stem Cell (2011) 1.87
Targeting nonclassical oncogenes for therapy in T-ALL. Cancer Cell (2012) 1.86
Hedgehog signaling is dispensable for adult hematopoietic stem cell function. Cell Stem Cell (2009) 1.84
Immunohistochemical diagnosis of renal neoplasms. Arch Pathol Lab Med (2011) 1.82
PR-Set7 and H4K20me1: at the crossroads of genome integrity, cell cycle, chromosome condensation, and transcription. Genes Dev (2012) 1.81
PAX2 and PAX8 expression in primary and metastatic müllerian epithelial tumors: a comprehensive comparison. Am J Surg Pathol (2011) 1.77
Distinct TCR signaling pathways drive proliferation and cytokine production in T cells. Nat Immunol (2013) 1.74
Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. Am J Surg Pathol (2010) 1.73
Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J Exp Med (2013) 1.71
Thymic selection revisited: how essential is it? Immunol Rev (2003) 1.71
Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med (2013) 1.71
Towards patient-based cancer therapeutics. Nat Biotechnol (2010) 1.63
A multistep adhesion cascade for lymphoid progenitor cell homing to the thymus. Proc Natl Acad Sci U S A (2006) 1.59
Glycogen synthase kinase-3 beta regulates NF-kappa B1/p105 stability. J Biol Chem (2003) 1.57
Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL. Nat Med (2012) 1.56
Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev (2010) 1.54
A unique function for cyclin D3 in early B cell development. Nat Immunol (2006) 1.51
Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. Oncotarget (2012) 1.50
Small cell carcinoma of the kidney: a clinicopathologic study of 14 cases. Hum Pathol (2011) 1.48
Plasma granulocyte colony-stimulating factor levels correlate with clinical outcomes in patients with acute lung injury. Crit Care Med (2009) 1.47
The BCL2A1 gene as a pre-T cell receptor-induced regulator of thymocyte survival. J Exp Med (2005) 1.46
PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study. Mod Pathol (2011) 1.45
Regulation of T-cell progenitor survival and cell-cycle entry by the pre-T-cell receptor. Immunol Rev (2006) 1.45
Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer. Urology (2008) 1.45
Tet2 facilitates the derepression of myeloid target genes during CEBPα-induced transdifferentiation of pre-B cells. Mol Cell (2012) 1.43
Roles of arabidopsis WRKY18, WRKY40 and WRKY60 transcription factors in plant responses to abscisic acid and abiotic stress. BMC Plant Biol (2010) 1.43
T-cell factor 1 is a gatekeeper for T-cell specification in response to Notch signaling. Proc Natl Acad Sci U S A (2011) 1.41
Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia. Cancer Cell (2012) 1.40
PAX-2 is a helpful marker for diagnosing metastatic renal cell carcinoma: comparison with the renal cell carcinoma marker antigen and kidney-specific cadherin. Arch Pathol Lab Med (2010) 1.38
Efficiency of RNA interference in the mouse hematopoietic system varies between cell types and developmental stages. Mol Cell Biol (2005) 1.37
Miz1 and HectH9 regulate the stability of the checkpoint protein, TopBP1. EMBO J (2008) 1.36
Involvement of MINK, a Ste20 family kinase, in Ras oncogene-induced growth arrest in human ovarian surface epithelial cells. Mol Cell (2005) 1.34
Notch signaling: switching an oncogene to a tumor suppressor. Blood (2014) 1.32
The PDZ protein tax-interacting protein-1 inhibits beta-catenin transcriptional activity and growth of colorectal cancer cells. J Biol Chem (2003) 1.32
Endothelial Jagged-1 is necessary for homeostatic and regenerative hematopoiesis. Cell Rep (2013) 1.32
Tracing lymphopoiesis with the aid of a pTalpha-controlled reporter gene. Nat Immunol (2002) 1.30
Regulation of hematopoietic stem cell differentiation by a single ubiquitin ligase-substrate complex. Nat Immunol (2010) 1.28
Pre-TCRalpha and TCRalpha are not interchangeable partners of TCRbeta during T lymphocyte development. J Exp Med (2004) 1.28
Hedgehog signaling controls thymocyte progenitor homeostasis and differentiation in the thymus. Nat Immunol (2006) 1.28
Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas. Clin Cancer Res (2008) 1.27
Rnai as an experimental and therapeutic tool to study and regulate physiological and disease processes. Annu Rev Physiol (2005) 1.27
Gas1 is induced by VE-cadherin and vascular endothelial growth factor and inhibits endothelial cell apoptosis. Blood (2003) 1.23
Close proximity to Igh is a contributing factor to AID-mediated translocations. Mol Cell (2012) 1.23